Global Long Acting Beta Agonist Market Insights, Forecast to 2030

Publication ID:

PB512243287

Publication Date:

December 18, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 4,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Long-acting beta-agonists or long-acting beta adrenergic receptor agonists are class of drugs used in the management of asthma by relaxing the muscles surrounding the bronchial tubes and facilitating the opening the airways wider. Long-acting beta-agonists have a longer duration of action of at least 12 hours.
Market Analysis and Insights: Global Long Acting Beta Agonist Market
The global Long Acting Beta Agonist market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Long Acting Beta Agonist is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Long Acting Beta Agonist is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The Europe market for Long Acting Beta Agonist is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The global key companies of Long Acting Beta Agonist include Sumitomo Dainippon Pharma, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim International, Mylan, Teva and Merck, etc. In 2023, the global top five players had a share approximately % in terms of revenue.
Long Acting Beta Agonist is widely used in various fields, such as Hospitals, Clinics, Ambulatory Surgical Center and Others, etc. Hospitals provides greatest supports to the Long Acting Beta Agonist industry development. In 2023, global % revenue of Long Acting Beta Agonist went into Hospitals filed and the proportion will reach to % in 2030.
Report Covers:
This report presents an overview of global market for Long Acting Beta Agonist market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Long Acting Beta Agonist, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Long Acting Beta Agonist, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Long Acting Beta Agonist revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Long Acting Beta Agonist market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Long Acting Beta Agonist revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation
By Company
Sumitomo Dainippon Pharma
AstraZeneca
GlaxoSmithKline
Boehringer Ingelheim International
Mylan
Teva
Merck
Segment by Type
Liquid
Tablet
Segment by Application
Hospitals
Clinics
Ambulatory Surgical Center
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Long Acting Beta Agonist in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Long Acting Beta Agonist companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Long Acting Beta Agonist revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Long Acting Beta Agonist Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Liquid
1.2.3 Tablet
1.3 Market by Application
1.3.1 Global Long Acting Beta Agonist Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Center
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Long Acting Beta Agonist Market Perspective (2019-2030)
2.2 Global Long Acting Beta Agonist Growth Trends by Region
2.2.1 Long Acting Beta Agonist Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Long Acting Beta Agonist Historic Market Size by Region (2019-2024)
2.2.3 Long Acting Beta Agonist Forecasted Market Size by Region (2025-2030)
2.3 Long Acting Beta Agonist Market Dynamics
2.3.1 Long Acting Beta Agonist Industry Trends
2.3.2 Long Acting Beta Agonist Market Drivers
2.3.3 Long Acting Beta Agonist Market Challenges
2.3.4 Long Acting Beta Agonist Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Long Acting Beta Agonist by Players
3.1.1 Global Long Acting Beta Agonist Revenue by Players (2019-2024)
3.1.2 Global Long Acting Beta Agonist Revenue Market Share by Players (2019-2024)
3.2 Global Long Acting Beta Agonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Long Acting Beta Agonist, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Long Acting Beta Agonist Market Concentration Ratio
3.4.1 Global Long Acting Beta Agonist Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Long Acting Beta Agonist Revenue in 2023
3.5 Global Key Players of Long Acting Beta Agonist Head office and Area Served
3.6 Global Key Players of Long Acting Beta Agonist, Product and Application
3.7 Global Key Players of Long Acting Beta Agonist, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Long Acting Beta Agonist Breakdown Data by Type
4.1 Global Long Acting Beta Agonist Historic Market Size by Type (2019-2024)
4.2 Global Long Acting Beta Agonist Forecasted Market Size by Type (2025-2030)
5 Long Acting Beta Agonist Breakdown Data by Application
5.1 Global Long Acting Beta Agonist Historic Market Size by Application (2019-2024)
5.2 Global Long Acting Beta Agonist Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Long Acting Beta Agonist Market Size (2019-2030)
6.2 North America Long Acting Beta Agonist Market Size by Type
6.2.1 North America Long Acting Beta Agonist Market Size by Type (2019-2024)
6.2.2 North America Long Acting Beta Agonist Market Size by Type (2025-2030)
6.2.3 North America Long Acting Beta Agonist Market Share by Type (2019-2030)
6.3 North America Long Acting Beta Agonist Market Size by Application
6.3.1 North America Long Acting Beta Agonist Market Size by Application (2019-2024)
6.3.2 North America Long Acting Beta Agonist Market Size by Application (2025-2030)
6.3.3 North America Long Acting Beta Agonist Market Share by Application (2019-2030)
6.4 North America Long Acting Beta Agonist Market Size by Country
6.4.1 North America Long Acting Beta Agonist Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Long Acting Beta Agonist Market Size by Country (2019-2024)
6.4.3 North America Long Acting Beta Agonist Market Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Long Acting Beta Agonist Market Size (2019-2030)
7.2 Europe Long Acting Beta Agonist Market Size by Type
7.2.1 Europe Long Acting Beta Agonist Market Size by Type (2019-2024)
7.2.2 Europe Long Acting Beta Agonist Market Size by Type (2025-2030)
7.2.3 Europe Long Acting Beta Agonist Market Share by Type (2019-2030)
7.3 Europe Long Acting Beta Agonist Market Size by Application
7.3.1 Europe Long Acting Beta Agonist Market Size by Application (2019-2024)
7.3.2 Europe Long Acting Beta Agonist Market Size by Application (2025-2030)
7.3.3 Europe Long Acting Beta Agonist Market Share by Application (2019-2030)
7.4 Europe Long Acting Beta Agonist Market Size by Country
7.4.1 Europe Long Acting Beta Agonist Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Long Acting Beta Agonist Market Size by Country (2019-2024)
7.4.3 Europe Long Acting Beta Agonist Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Long Acting Beta Agonist Market Size (2019-2030)
8.2 China Long Acting Beta Agonist Market Size by Type
8.2.1 China Long Acting Beta Agonist Market Size by Type (2019-2024)
8.2.2 China Long Acting Beta Agonist Market Size by Type (2025-2030)
8.2.3 China Long Acting Beta Agonist Market Share by Type (2019-2030)
8.3 China Long Acting Beta Agonist Market Size by Application
8.3.1 China Long Acting Beta Agonist Market Size by Application (2019-2024)
8.3.2 China Long Acting Beta Agonist Market Size by Application (2025-2030)
8.3.3 China Long Acting Beta Agonist Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Long Acting Beta Agonist Market Size (2019-2030)
9.2 Asia Long Acting Beta Agonist Market Size by Type
9.2.1 Asia Long Acting Beta Agonist Market Size by Type (2019-2024)
9.2.2 Asia Long Acting Beta Agonist Market Size by Type (2025-2030)
9.2.3 Asia Long Acting Beta Agonist Market Share by Type (2019-2030)
9.3 Asia Long Acting Beta Agonist Market Size by Application
9.3.1 Asia Long Acting Beta Agonist Market Size by Application (2019-2024)
9.3.2 Asia Long Acting Beta Agonist Market Size by Application (2025-2030)
9.3.3 Asia Long Acting Beta Agonist Market Share by Application (2019-2030)
9.4 Asia Long Acting Beta Agonist Market Size by Region
9.4.1 Asia Long Acting Beta Agonist Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Long Acting Beta Agonist Market Size by Region (2019-2024)
9.4.3 Asia Long Acting Beta Agonist Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Long Acting Beta Agonist Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Long Acting Beta Agonist Market Size by Type
10.2.1 Middle East, Africa, and Latin America Long Acting Beta Agonist Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Long Acting Beta Agonist Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Long Acting Beta Agonist Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Long Acting Beta Agonist Market Size by Application
10.3.1 Middle East, Africa, and Latin America Long Acting Beta Agonist Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Long Acting Beta Agonist Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Long Acting Beta Agonist Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Long Acting Beta Agonist Market Size by Country
10.4.1 Middle East, Africa, and Latin America Long Acting Beta Agonist Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Long Acting Beta Agonist Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Long Acting Beta Agonist Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Sumitomo Dainippon Pharma
11.1.1 Sumitomo Dainippon Pharma Company Details
11.1.2 Sumitomo Dainippon Pharma Business Overview
11.1.3 Sumitomo Dainippon Pharma Long Acting Beta Agonist Introduction
11.1.4 Sumitomo Dainippon Pharma Revenue in Long Acting Beta Agonist Business (2019-2024)
11.1.5 Sumitomo Dainippon Pharma Recent Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Company Details
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Long Acting Beta Agonist Introduction
11.2.4 AstraZeneca Revenue in Long Acting Beta Agonist Business (2019-2024)
11.2.5 AstraZeneca Recent Developments
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Details
11.3.2 GlaxoSmithKline Business Overview
11.3.3 GlaxoSmithKline Long Acting Beta Agonist Introduction
11.3.4 GlaxoSmithKline Revenue in Long Acting Beta Agonist Business (2019-2024)
11.3.5 GlaxoSmithKline Recent Developments
11.4 Boehringer Ingelheim International
11.4.1 Boehringer Ingelheim International Company Details
11.4.2 Boehringer Ingelheim International Business Overview
11.4.3 Boehringer Ingelheim International Long Acting Beta Agonist Introduction
11.4.4 Boehringer Ingelheim International Revenue in Long Acting Beta Agonist Business (2019-2024)
11.4.5 Boehringer Ingelheim International Recent Developments
11.5 Mylan
11.5.1 Mylan Company Details
11.5.2 Mylan Business Overview
11.5.3 Mylan Long Acting Beta Agonist Introduction
11.5.4 Mylan Revenue in Long Acting Beta Agonist Business (2019-2024)
11.5.5 Mylan Recent Developments
11.6 Teva
11.6.1 Teva Company Details
11.6.2 Teva Business Overview
11.6.3 Teva Long Acting Beta Agonist Introduction
11.6.4 Teva Revenue in Long Acting Beta Agonist Business (2019-2024)
11.6.5 Teva Recent Developments
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Long Acting Beta Agonist Introduction
11.7.4 Merck Revenue in Long Acting Beta Agonist Business (2019-2024)
11.7.5 Merck Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Sumitomo Dainippon Pharma
AstraZeneca
GlaxoSmithKline
Boehringer Ingelheim International
Mylan
Teva
Merck

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂